Crossmark

Maintenance sorafenib is superior to prophylactic donor lymphocyte infusion at improving the prognosis of acute myeloid leukemia with FMS-like tyrosine kinase 3 internal tandem duplication after allogeneic hematopoietic stem cell transplantation

Crossref DOI link: https://doi.org/10.1038/s41409-020-01015-w

Published Online: 2020-08-04

Published Print: 2021-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Shi, Jimin https://orcid.org/0000-0002-1852-326X
Cao, Liqin

Luo, Yi

Zhao, Yanmin

Tan, Yamin

Yu, Jian

Lai, Xiaoyu

Zhu, Yuanyuan

Hu, Yongxian

He, Jingsong

Sun, Jie

Zheng, Weiyan

Wei, Guoqing

Huang, He https://orcid.org/0000-0002-2723-1621
Funding

Funding for this research was provided by:

Science and Technology Department of Zhejiang Province (2015C03038)

National Natural Science Foundation of China (81870153)
License Information

Text and Data Mining valid from 2020-08-04

Version of Record valid from 2020-08-04
More Information

Article History

Received: 22 July 2019

Revised: 15 July 2020

Accepted: 24 July 2020

First Online: 4 August 2020

Compliance with ethical standards

:

: The authors declare that they have no conflict of interest.

Document is current

Any future updates will be listed below